Loading...

Chromadex Corp
NASDAQ:CDXC

Watchlist Manager
Chromadex Corp Logo
Chromadex Corp
NASDAQ:CDXC
Watchlist
Price: 1.7 USD -2.86% Market Closed
Updated: Dec 6, 2022

Intrinsic Value

The intrinsic value of one CDXC stock under the Base Case scenario is 3.43 USD. Compared to the current market price of 1.7 USD, Chromadex Corp is Undervalued by 51%.

The Intrinsic Value is calculated as the average of the two valuation methods:

CDXC Intrinsic Value
Base Case
3.43 USD
Undervaluation 51%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

CDXC Profitability Score
Profitability Due Diligence

Chromadex Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
30/100
Profitability
Score

Chromadex Corp's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

CDXC Solvency Score
Solvency Due Diligence

Chromadex Corp's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low Altman Z-Score
Long-Term Liabilities
Short-Term Liabilities
Low D/E
51/100
Solvency
Score

Chromadex Corp's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
61%
Gross Margin
-33%
Operating Margin
-30%
Net Margin
-29%
FCF Margin
-72%
ROE
-112%
ROIC
Other

CDXC Capital Structure
Chromadex Corp

Market Capitalization 116M USD
Total Debt 0 USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 13.1M USD
Short-Term Investments 0 USD
Enterprise Value 103M USD

Wall St
Price Targets

CDXC Price Targets Summary
Chromadex Corp

Wall Street analysts forecast CDXC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CDXC is 6.18 USD with a low forecast of 2.12 USD and a high forecast of 10.5 USD.

Lowest
Price Target
2.12 USD
25% Upside
Average
Price Target
6.18 USD
263% Upside
Highest
Price Target
10.5 USD
518% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

CDXC Competitors
Chromadex Corp

CDXC Suppliers & Customers
Chromadex Corp

Chromadex Corp has 2 key suppliers from 1 countries and 1 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Retail industry.

Suppliers Map

Chromadex Corp has 2 key customers from 2 countries and 2 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Retail industry.

Ownership

CDXC Insider Trading
Buy and sell transactions by insiders

Chromadex Corp insiders have only bought shares in the past 12 months.

During the last 12 months Chromadex Corp insiders bought 1.5M USD , and have not sold any shares. The last transaction was made on Dec 6, 2022 by Fried Robert N (Cheif Executive Officer), who bought 100k USD worth of CDXC shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
2
1.3M USD
3-6
months
1
99.9k USD
6-9
months
1
54k USD
9-12
months
No Insider Transactions
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
1.3M USD
1.3M
6 Months
N/A
1.4M USD
1.4M
9 Months
N/A
1.5M USD
1.5M
12 Months
N/A
1.5M USD
1.5M
Purchases
93
Sales
12
Why is insider trading important?

Shareholder Return

CDXC Price
Chromadex Corp

1M 1M
-21%
6M 6M
-11%
1Y 1Y
-62%
3Y 3Y
-56%
5Y 5Y
-73%
Annual Price Range
1.7
52w Low
1.19
52w High
4.74
Price Metrics
Average Annual Return -2.47%
Standard Deviation of Annual Returns 31.15%
Max Drawdown -94%
Shares Statistics
Market Capitalization 116M USD
Shares Outstanding 74 468 704
Percentage of Shares Shorted 2.81%

Company Profile

Chromadex Corp

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

116M USD

Dividend Yield

0%

Description

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 115 full-time employees. The company went IPO on 2007-06-25. NAD+ is a coenzyme and a regulator of cellular metabolism. The company operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Contact

CALIFORNIA
Los Angeles
10900 Wilshire Blvd Ste 600
+13103886706.0
https://chromadex.com/default.aspx

IPO

2007-06-25

Employees

115

Officers

Co-Founder & Chairman
Mr. Frank Louis Jaksch Jr.
CEO & Director
Mr. Robert N. Fried
Sr. VP of Fin., VP of Investor Relations & Interim CFO
Ms. Brianna Gerber
Sr. VP of Global Regulatory & Scientific Affairs
Dr. Andrew Shao Ph.D.
Sr. VP of Legal & Corp. Sec.
Heather Van Blarcom
VP of Global Marketing & Communications
Alex Worsham
Show More
Chief Marketing Officer
Mr. Fadi Karam
Sr. VP of People Matters
David Kroes
Managing Director of Asia Pacific
Ms. Chu Yan
Managing Director of LifeSci Advisors
Tom Shumaker
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one CDXC stock?

The intrinsic value of one CDXC stock under the Base Case scenario is 3.43 USD.

Is CDXC stock undervalued or overvalued?

Compared to the current market price of 1.7 USD, Chromadex Corp is Undervalued by 51%.